Home › Research › Treatments
Review on Alzheimer-Suppressing Potential of different Medicinal plant
Vikas G. Pawar, Arshu Patel, Aarti R. Sanap. Research Journal of Science and Technology, 2026-04-25
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Progressive neurodegenerative disorder i.e. Alzheimer’s disease (AD) is characterized by cognitive decline, oxidative stress, and cholinergic dysfunction, β-amyloid aggregation, tau hyperphosphorylation. Plant-derived neuroprotective agents have gained increasing scientific attention due to their multi-target mechanisms and favorable safety profiles. This review aims to highlight the Alzheimer’s-suppressing potential of four traditionally important medicinal plants: Convolvulus pluricaulis, Curcuma longa, Withania somnifera, and Bacopa monnieri. C. pluricaulis has been reported to exhibit nootropic and anxiolytic effects mainly via cholinesterase inhibition and antioxidant activity. C. longa (Curcumin) has strong anti-amyloid, anti-inflammatory, and metal-chelating properties, offering protection against plaque formation and neuronal toxicity. W. somnifera (Withanolide) promotes synaptic regeneration, decreases oxidative stress, and provides amyloid and tau pathology modulation. B. monnieri, rich in bacosides and flavonoids, enhances cognitive performance by reducing oxidative damage, improving cholinergic function, and inhibiting β-amyloid aggregation. Altogether, these botanicals act through complementary pathways, including antioxidant defense, anti-inflammatory modulation, neurotransmitter regulation, and prevention of amyloid/tau pathology, thereby making them promising candidates for the integrative management of AD. Further clinical validation is essential to determine standardized doses and the long-term efficacy of these extracts, as well as synergistic potential in combination therapies.
What this study adds
Evidence grade: Low
This review describes four medicinal plants whose compounds are reported to act through antioxidant, anti-inflammatory, cholinergic and anti-amyloid/tau mechanisms relevant to Alzheimer's disease. It is a summary of reported plant properties and does not provide clinical trial evidence that these plants treat, cure or prevent the disease in people.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Pawar, V. G., Patel, A., & Sanap, A. R. (2026). Review on Alzheimer-Suppressing Potential of different Medicinal plant. Research Journal of Science and Technology. https://doi.org/10.52711/2349-2988.2026.00026
Vancouver
Pawar VG, Patel A, Sanap AR. Review on Alzheimer-Suppressing Potential of different Medicinal plant. Research Journal of Science and Technology. 2026. doi:10.52711/2349-2988.2026.00026.
BibTeX
@article{pawar2026-f8a6f497,
author = {Pawar, Vikas G. and Patel, Arshu and Sanap, Aarti R.},
title = {{Review on Alzheimer-Suppressing Potential of different Medicinal plant}},
journal = {Research Journal of Science and Technology},
year = {2026},
doi = {10.52711/2349-2988.2026.00026},
url = {https://doi.org/10.52711/2349-2988.2026.00026}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- C. longa (Curcumin) has strong anti-amyloid, anti-inflammatory, and metal-chelating properties, offering protection against plaque formation and neuronal toxicity.
- W. somnifera (Withanolide) promotes synaptic regeneration, decreases oxidative stress, and provides amyloid and tau pathology modulation.
- B. monnieri, rich in bacosides and flavonoids, enhances cognitive performance by reducing oxidative damage, improving cholinergic function, and inhibiting β-amyloid aggregation.
- Altogether, these botanicals act through complementary pathways, including antioxidant defense, anti-inflammatory modulation, neurotransmitter regulation, and prevention of amyloid/tau pathology, thereby making them promising candidates for the integrative management of AD.
- Further clinical validation is essential to determine standardized doses and the long-term efficacy of these extracts, as well as synergistic potential in combination therapies.
Why it matters
This review describes four medicinal plants whose compounds are reported to act through antioxidant, anti-inflammatory, cholinergic and anti-amyloid/tau mechanisms relevant to Alzheimer's disease. It is a summary of reported plant properties and does not provide clinical trial evidence that these plants treat, cure or prevent the disease in people.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 25/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 24 of the 96 points we could judge it on, which is 25 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Research Journal of Science and Technology) |
| Journal's citation record | 0 / 4 | Research Journal of Science and Technology: journal h-index 15 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Aarti R. Sanap holds only 4 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Pravara Rural College of Pharmacy Pravaranagar: institution h-index 31 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 24 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 24 of the 96 points we could judge it on is 25 out of 100. |
| Total | 25 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also in Treatments
203 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.